NCT02095834View on ClinicalTrials.gov

Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 24, 2014

Primary Completion Date

January 7, 2021

Study Completion Date

January 7, 2021

Conditions

Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma

Interventions

DRUG

Bendamustine Hydrochloride

Given IV

DRUG

Carfilzomib

Given IV

DRUG

Dexamethasone

Given PO or IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02095834 - Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter